Clinical Trial Update: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION) [Phase 3]

View source ↗

Summary

Phase 3 trial of Tocilizumab (RoActemra/Actemra) in rheumatoid arthritis patients with inadequate response to DMARDs has completed. Results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2014-07-10